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•	 heterogeneity 
of Anaplastic 
Lymphoma Kinase 
Gene Rearrangement 
in non-small-Cell 
Lung Carcinomas: A 
Comparative study 
Between small Biopsy and 
excision samples
IHC-positive patients, of which 6 were given crizotinib 
treatment. Observation areas (6–10) were determined 
in each excision specimen, and the number of ALK 
FISH-positive areas (≥15% rearrangement detected) 
was assessed for evaluation of heterogeneity of ALK 
rearrangement. In small biopsy specimens, ALK FISH 
score was defined as positive (≥15% rearrangement 
detected), equivocal (5% to 14% rearrangement 
detected), or negative (<4% rearrangement detected). 
The results showed that ALK rearrangement was found 
in 50 out of 64 observation areas (81.8%) in 9 excision 
specimens. ALK FISH-positivity was observed in 100% 
of excision specimens (6/6) while it was only detected 
in 50% (3/6) of the small biopsy specimens of the same 
patients; 33% of these samples were equivocal (2/6, 
from patients responded to crizotinib), and 17% were 
negative (1/6). Taken together, the findings demonstrated 
ALK rearrangement heterogeneity in NSCLC specimens 
using FISH, and suggested that IHC-positive/FISH-
equivocal cases in small biopsy specimens should not be 
considered as true ALK “false negatives”. (p. 800)
H2228 ALK IHC ALK FISH
The authors set out to evaluate the heterogeneity of anaplastic 
lymphoma kinase (ALK) rearrangement in non-small cell lung 
cancer (NSCLC) excision samples using fluorescent in situ 
hybridization (FISH), and compare the FISH score of ALK 
rearrangement in excision and small biopsy specimens from 
the same patient. ALK FISH-positivity was analyzed in 20 ALK 
•	 Patterns of Recurrence and 
survival after surgery or 
stereotactic Radiotherapy 
for early stage nsCLC
Center Groningen, Netherlands (2007–2010). Patients 
were 10 years younger, with better WHO performance 
and less comorbidities, in the group treated with 
surgery versus that with SABR. Between the SABR 
arm and the surgery arm, there was no difference in OS 
(adjusted hazard ratio [HR] 1.07; p=0.73), local control 
(adjusted sub-HR 1.21; p=0.75) and distant recurrences 
(adjusted sub-HR 1.01; p=0.97). However, significantly 
higher locoregional recurrences were observed in the 
SABR arm versus the surgery arm (adjusted sub-HR 
2.51; p=0.028). Independent predictive factors for OS 
were nodal failure (HR 2.16) and distant metastases 
(HR 2.12), but not local failure (HR 1.00). The 
authors concluded that although adjusted OS was 
similar between patients with stage I NSCLC treated 
with surgery and SABR, the SABR group had worse 
locoregional tumor control as a result of more nodal 
failures versus surgery. The findings underscored the 
importance of improving mediastinal and hilar staging 
for optimal treatment decisions. (p. 826)
In this study, the authors assessed the overall survival (OS) and 
patterns of tumor recurrence in 340 patients with stage I non-small 
cell lung cancer (NSCLC), who received surgery or stereotactic 
ablative radiotherapy (SABR). They retrospectively analyzed 
clinical data from patients with fluoro-deoxyglucose positron 
emission tomography/computed tomography-staged NSCLC treated 
with surgery (n=143) or SABR (n=197) at the University Medical 
Image source: NCI
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The aim of this study was to evaluate the mass 
spectrometry-based Sequenom LungCarta panel and 
MassARRAY platform using DNA extracted from 
a single 5 μM formalin-fixed paraffin-embedded 
non-small cell lung cancer (NSCLC) tissue section 
for diagnostic mutation profiling. Ninety NSCLC 
samples, consisting of 72 lung biopsies, 13 metastatic 
tissue biopsies, 3 resections, and 2 cytology samples, 
were analyzed for mutations and were subsequently 
validated by a combination of molecular techniques. 
The Sequenom assay detected 55 mutations in TP53 
(22), KRAS (15), EGFR (5), MET (3), PIK3CA (3), 
STK11 (2), NRF-2 (2), EPHA5 (1), EPHA3 (1), and 
MAP2K1 (1) in 52% of the samples tested. They found 
that next-generation sequencing (NGS) detected 7 
additional TP53 mutations but NGS used more tumor 
sections of greater thickness (5 × 10 μM) versus that for 
the Sequenom assay (1 × 5 μM). The authors concluded 
that the Sequenom Lung Carta panel is a clinically 
useful diagnostic screening test for small biopsy 
samples of NSCLC. This assay is capable of screening 
214 mutations across 26 genes, and confidently detects 
mutations at neoplastic cell content levels of 10% and 
above from a single 5 μM section. (p. 784)
•	 Diagnostic Mutation 
Profiling and Validation 
of non–small-Cell Lung 
Cancer small Biopsy 
samples using a high 
Throughput Platform
•	 updated Frequency of 
eGFR and KRAs Mutations 
in nonsmall-Cell Lung 
Cancer in Latin America: 
The Latin-American 
Consortium for the 
Investigation of Lung 
Cancer
population consists of patients with median age of 
62.2 ± 12.3 years, 53.5% women, 46.7% with a history 
of smoking, and 95.2% with adenocarcinoma. EGFR 
mutations were found in 26.0% of the overall study 
population, with 14.4% from Argentina, 34.3% from 
Mexico, 24.7% from Columbia, 51.1% from Peru, 
27.3% from Panama, and 31.4% from Costa Rica. 
KRAS mutations were detected in 14.0% of the overall 
population. The EGFR mutations in patients with 
adenocarcinoma were independently correlated with 
female, nonsmoker status, mestizo/indigenous ethnicity, 
and the absence of KRAS mutation (all p<0.001). 
Patients treated with EGFR inhibitors demonstrated an 
overall response rate of 60.6%, a median progression-
free survival of 15.9 months, and overall survival of 
32 months. Taken together, the findings confirmed 
that the frequency of EGFR mutations in Latin 
America is intermediate between that in the Asian and 
Caucasian populations, and also supported the genetic 
heterogeneity of NSCLC around the world. (p. 838)
This report provided an update on the distribution of epidermal 
growth factor receptor (EGFR) and KRAS mutations in Latin 
American patients with non-small cell lung cancer (NSCLC). In 
previous studies, 40% Asian and 15% Caucasian were found to 
harbor the EGFR mutations. The present study included 5738 
NSCLC samples from Argentina (1713), Mexico (1417), Colombia 
(1939), Peru (393), Panama (174), and Costa Rica (102). The study 
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ReseARCh WATCh
•	 Overall Response Rate, 
Progression-Free survival, 
and Overall survival With 
Targeted and standard 
Therapies in Advanced 
non–small-Cell Lung 
Cancer: A us Food and 
Drug Administration Trial-
Level and Patient-Level 
Analyses
mutation-positive population and one trial in ALK-
positive population. At the trial level, strong association 
between ORR and PFS was observed (R2 = 0.89), but 
not between ORR and OS (R2 = 0.09), and between 
OS and PFS (R2 = 0.08). At the patient level, ORR was 
significantly associated with improved PFS (hazard ratio 
[HR] 0.40) and OS (HR 0.40), when compared with non-
responders. To conclude, the lack of correlation between 
ORR and OS, and between OS and PFS at the trial level 
was likely a result of cross-over and longer survival after 
progression in trials of targeted therapies and first-line 
treatments. ORR and PFS was strongly associated at trial 
and patient levels, indicating a dramatic effect on ORR 
from a therapy in advanced NSCLC may have a large 
effect on PFS.
Blumenthal GM, Karuri SW, Zhang H, et al. Overall 
Response Rate, Progression-Free Survival, and Overall 
Survival With Targeted and Standard Therapies in Advanced 
Non-Small-Cell Lung Cancer: A US Food and Drug 
Administration Trial-Level and Patient-Level Analyses. 
J Clin Oncol, doi:10.1200/jco.2014.59.0489 (2015).
tobacco-induced diseases including coronary artery 
disease and chronic obstructive pulmonary disease. The 
central focus of the Workshop was on the issues regarding 
the national implementation of high quality low-dose 
computed tomography (LDCT). Efforts in accelerating 
progress in the integration of quantitative imaging into 
early lung cancer have been largely successful as a 
result of collaborations with professional organizations, 
including the Radiological Society of North America 
and the formation of Quantitative Imaging Biomarker 
Alliance. Included in the discussion were methodologies 
issues with quantitative imaging, the impact of screening 
management on quantitative imaging, the status of harms 
reduction (dose minimization), the precision of current 
lung cancer screening quantitation, future advances on 
evaluation of other thoracic structures while screening, 
and other applications in lung cancer management. 
The cost-benefit analysis of LDCT estimated $25,000 
per life-year saved, comparable to mammography and 
cervical cancer screening, and similar to colorectal 
screening. Important actions relative to health policy in 
the national implementation of lung cancer screening 
were recommended: firstly, to request Centers for 
Medicare and Medicaid Services for full reimbursement 
coverage of LDCT screening at a national level; secondly, 
to support the Department of Defense and its Healthy 
Base Initiative; and finally, to commission a study by 
the Institute of Medicine of the National Academy of 
Sciences on imaging research as it relates to lung and 
heart diseases. (p. 762)
•	 Lung Cancer Workshop 
XI: Tobacco-Induced 
Disease: Advances in 
Policy, Early Detection and 
Management
Months (m)
Pr
og
re
ss
io
n
fr
ee
su
rv
iv
al
to
EG
FR
TK
I EGFR mutation
Median 15.9 months [CI95% 12.5-19.5]
No EGFR mutation
Median 5.5  months [CI95% 3.6-7.4]
P< 0.001
Months (m)
O
ve
ra
ll
Su
rv
iv
al
to
EG
FR
TK
I
EGFR mutation
Median 32 months [CI95% 26.5-37.6]
No EGFR mutation
Median 9.6  months [CI95% 6.8-12.4]
P< 0.001
A
B
The special article covers the Prevent Cancer Foundation Lung 
Cancer Workshop XI: Tobacco-Induced Disease: Advances in 
Policy, Early Detection and Management held in New York, NY in 
2014. The steering committee consists of technical experts David 
Yankelevitz, Thomas Baer, Rick Avila, Carolyn Aldigé of the Prevent 
Cancer Foundation, and Laurie Fenton Ambrose of the Lung Cancer 
Alliance. The two goals of the Workshop were to improve quantitative 
imaging for management of early lung cancer through innovative 
research on its use to assess new treatments, and to review progress 
of the application of quantitative imaging for lung cancer and other 
The US FDA conducted an analysis of 14 randomized, active-
controlled trials of treatments involving 12,567 patients with 
advanced non-small cell lung cancer (NSCLC) to elucidate the 
relationships between overall response rate (ORR), progression-
free survival (PFS) and overall survival (OS) at trial and patient 
levels. Experimental treatments in the trials included crizotinib, 
afatinib, erlotinib, nab-paclitaxel plus carboplatin, vandetanib, 
cetuximab, gefitinib, bevacizumab, pemetrexed plus cisplatin, and 
pemetrexed alone. Two trials assessed targeted therapies in EGFR 
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or cfDNA predicts worse OS (hazard ratio [HR] 2.70; 
P<0.001) and progression-free survival (PFS) (hazard 
ratio [HR] 2.04; P=0.008). Patients with L858R 
mutation in both tumor tissue and cfDNA had a median 
OS of 13.7 months while those with the mutation in 
tumor tissue but not cfDNA had a median OS of 27.7 
months (HR 2.22; P=0.03). Erlotinib therapy was the 
sole independent predictor of prolonged PFS in the 
multivariate analysis of patients with EGFR mutations 
in cfDNA (HR 0.41; P=0.003). Taken together, L858R 
mutation in cfDNA is associated with poorer survival; 
the assay used in this study could efficiently evaluate 
these mutations in cfDNA, which could be a novel 
surrogate prognostic marker in the study population.
Karachaliou N, Mayo-de las Casas C, Queralt C, 
et al. Association of egfr l858r mutation in circulating 
free dna with survival in the eurtac trial. JAMA 
Oncology, doi:10.1001/jamaoncol.2014.257 (2015).
•	 Association of EGFR L858R 
Mutation in Circulating 
Free DnA With survival in 
the euRTAC Trial
The prespecified analysis of the EURTAC trial (2007–2011) 
aimed to evaluate the use of circulating free DNA (cfDNA) from 
blood samples as a surrogate for tumor biopsy to determine the 
association of EGFR mutations in cfDNA with outcome in patients 
with advanced non-small cell lung cancer (NSCLC) harboring 
epidermal growth factor receptor (EGFR) mutations. Patients had 
no prior chemotherapy for metastatic disease, and were treated with 
erlotinib or chemotherapy in the EURTAC study. Using a novel 
peptide nucleic acid–mediated 5´ nuclease real-time polymerase 
chain reaction (TaqMan) assay, EGFR mutations were detected in 
cfDNA from 76 of 97 blood samples (78%). Shorter median overall 
survival (OS) was found in patients harboring L858R mutation 
versus exon 19 deletion in cfDNA (13.7 vs. 30.0 months; P<0.001). 
According to univariate analysis, L858R mutation in tumor tissue 
•	 Crizotinib Therapy 
for Advanced Lung 
Adenocarcinoma and a 
ROS1 Rearrangement: 
Results From the euROs1 
Cohort
Among the 30 patients evaluable for progression-free 
survival (PFS), a median PFS of 9.1 months and a 
PFS rate of 44% at 12 months were achieved, with no 
unexpected side effects. Among the 26 patients who 
were treated with pemetrexed alone or in combination 
with platinum, before or after the crizotinib treatment, a 
response rate of 57.7% and a median PFS of 7.2 months 
were achieved. The findings indicated substantial 
activity of crizotinib in patients with advanced lung 
adenocarcinoma harboring a ROS1 rearrangement, 
supporting screening lung cancer patients for ROS1 for 
the treatment with crizotinib or other ROS1 inhibitors.
Mazieres J, Zalcman G, Crino L, et al. Crizotinib 
Therapy for Advanced Lung Adenocarcinoma and a ROS1 
Rearrangement: Results From the EUROS1 Cohort. J Clin 
Oncol, doi:10.1200/jco.2014.58.3302 (2015).
The authors conducted a retrospective study of crizotinib treatment 
in 32 European patients with stage IV lung adenocarcinoma, 
harboring ROS1 rearrangement as shown by fluorescent in situ 
hybridization. The study population had a median age of 50.5 
years, 64.5% women and 67.7% never-smokers. Of the 29 patients 
evaluable for best response, 4 had disease progression, 2 had stable 
disease, and 24 had objective response, which included 5 complete 
responses (overall response rate: 80%; disease control rate: 86.7%). 
accumulation of p-BQ in the lung, in conjunction with 
damage of alveolar cells and emphysema, following 
progressive exposure to CS or p-BQ. Arylation, 
oxidative stress, inflammation, and apoptosis were 
observed. The p-BQ accumulation in the lung and the 
pathogenesis of emphysema was shown to be prevented 
by 30 mg/kg body weight/d of vitamin C, which could 
be an antagonist of p-BQ. Taken together, the evidence 
suggested that inactivation of p-BQ via a moderately 
high dose of vitamin C could prevent the development 
of emphysema in chronic smokers.
Ghosh A, Ganguly S, Dey N, et al. Causation of 
Cigarette Smoke–Induced Emphysema by p-Benzoquinone 
and Its Prevention by Vitamin C. American journal of 
respiratory cell and molecular biology 52, 315–322, 
doi:10.1165/rcmb.2013-0545OC (2014).
•	 Causation of Cigarette 
smoke–Induced 
emphysema by p-Benzo-
quinone and Its Prevention 
by Vitamin C
The authors set out to show the cause of pathogenesis of lung 
injury in emphysema, and discovered that p-benzoquinone (p-BQ) 
released after cigarette smoke (CS) exposure in the lungs of the 
guinea pigs contributed to the damage of alveolar cells leading to 
emphysema. They also demonstrated that the condition could be 
prevented by vitamin C. Guinea pigs were vitamin C-restricted 
and subjected to whole-body CS exposure from Kentucky research 
cigarettes (3R4F) per day or intramuscular injection of similar 
amount p-BQ to that released in CS-exposed lungs with and without 
oral supplementation of vitamin C. The results showed progressive 
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•	 The use of Legal, Illegal 
and Roll-Your-Own 
Cigarettes to Increasing 
Tobacco excise Taxes and 
Comprehensive Tobacco 
Control Policies: Findings 
from the ITC uruguay 
survey
This study analyzed whether smokers switch to 
manufactured illegal or roll-your-own (RYO) 
cigarettes as a result of a change in their relative price 
in Uruguay after adjusting for covariates, such as 
sociodemographic characteristics, smokers’ exposure 
to antismoking messaging, health warning labels and 
tobacco marketing. The results demonstrated a 10% 
increase in the relative price ratio of legal to RYO 
cigarettes correlating with a 4.6% increase in the switch 
from manufactured legal cigarettes to RYO cigarettes 
(p≤0.05). Lower odds of switching from manufactured 
legal cigarettes to RYO were associated with increased 
exposure to antismoking messaging (p≤0.05). There was 
no significant association between the manufactured 
illegal to legal cigarette price ratios and switching 
to manufactured illegal cigarettes from legal ones, 
indicating a rise in prices of legal cigarettes does not 
trigger smokers to switch to manufactured illegal ones. 
To conclude, the authors urged policymakers to narrow 
price variability in the tobacco market in an attempt to 
enhance the effectiveness in smoking reduction through 
increased taxes and prices. Additionally, reducing 
the switch to cheaper RYO cigarettes by boosting 
antismoking messaging could lower tax avoidance in 
Uruguay.
Curti D, Shang C, Ridgeway W, Chaloupka FJ, 
Fong GT. The use of legal, illegal and roll-your-own 
cigarettes to increasing tobacco excise taxes and 
comprehensive tobacco control policies: findings from 
the ITC Uruguay survey. Tobacco control, doi:10.1136/
tobaccocontrol-2014–051890 (2015).
•	 Gender equality and 
smoking: A Theory-Driven 
Approach to smoking 
Gender Differences in 
spain
observed in the youngest birth cohort of the study (born 
1980–1990) and highly educated women. Also, the first 
to show a decline in smoking prevalence were highly 
educated women versus those less educated. The authors 
concluded that the dramatic drop in gender inequality in 
Spain over the past 5 decades coincided with converging 
trends in smoking prevalence for men and women. 
Wide variation in patterns of smoking prevalence by 
birth cohort and education levels was observed. They 
recommended gender-sensitive measures in tobacco 
control and policies in countries at the beginning of the 
tobacco epidemic.
Bilal U, Beltran P, Fernandez E, Navas-Acien 
A, Bolumar F, Franco M. Gender equality and 
smoking: a theory-driven approach to smoking gender 
differences in Spain. Tobacco control, doi:10.1136/
tobaccocontrol-2014–051892 (2015).
This study investigated the relationship of changes in gender 
equality and variation in smoking prevalence stratified by gender, 
education and birth cohort in Spain from representative National 
Health Surveys (1960 to 2010). The Gender Inequality Index 
(GII) was measured in 5-year intervals, ranging from 0 to 1 (1 
being the highest inequality), and covered reproductive health, 
empowerment and labor market. The findings showed a decline 
in GII in Spain from 0.65 to 0.09 over the past 5 decades, which 
was inversely correlated to an increasing female-male smoking 
ratio. Compared with men, similar smoking prevalences were 
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Medicare will now cover low-dose computed 
tomography (LDCT) screening for lung cancer once per 
year for Medicare beneficiaries who are 55–77 years of 
age, current smokers or those who have quit smoking 
within the last 15 years, have at least 30 pack-years of 
smoking history, and obtained a written order from a 
physician or qualified non-physician practitioner. The 
coverage includes a visit for counseling and shared 
decision-making on the risks and benefits of lung cancer 
screening. The national coverage determination also 
includes required data collection and specific criteria for 
coverage eligibility for radiologists and imaging centers.
neWs In BRIeF
•	 CMs: national Coverage 
Determination for 
Low-Dose Computed 
Tomography screening for 
Lung Cancer
Image source: FDA
•	 Chemotherapy Trials for 
Advanced Cancers of 
the Lung and Pancreas 
Overestimate survival for 
elderly Medicare Patients
or lung cancer patients aged 65 or older, treated with 
one of three recommended first-line chemotherapies. 
Their survival data were compared with that of clinical 
trial patients (n=937) of the same diagnosis and disease 
stage but without age restrictions. Comparing elderly 
Medicare patients with clinical trial patients, the 
survival times in stage IV non-small cell lung cancer 
were 7.3 versus 8.9 months (P = 0.91) treated with 
carboplatin and paclitaxel, and 8.2 versus 10.2 months 
(P ≤ 0.01) in extensive small cell lung cancer treated 
with cisplatin/etoposide. Younger Medicare patients had 
similar survival times to clinical trial patients, indicating 
that choice of usual-care treatment by physicians for this 
group has been reasonable. The findings underscored 
the need to take into account of the various factors like 
functional status, comorbidity and general health status 
in comprehensive geriatric assessments, leading to 
better patient stratification for treatments.
Lamont et al. reported in the Journal of National Cancer Institute 
that clinical trial results assessing chemotherapy for advanced 
pancreatic and lung cancers demonstrated a tendency of correct 
estimation of survival for Medicare patients aged 65–74 years, but 
overestimation of survival in older Medicare patients by 6–8 weeks. 
The authors analyzed Surveillance, Epidemiology, and End Results 
Program (SEER)–Medicare data of 14,097 advanced pancreatic 
Image source: NCI
•	 FDA Grants Orphan Drug 
Designation to Vs-5584 for 
Mesothelioma
VS-5584, a Verastem PI3K inhibitor and dual 
inhibitor of mTORC1 and mTORC2, receives orphan 
drug designation from the FDA for the treatment 
of mesothelioma. Following preclinical findings 
that demonstrated synergistic effect from VS-5584 
in combination with VS-6063 (defactinib) in 
mesothelioma, a phase I study is currently underway to 
assess the combination regimen in patients with relapsed 
or progressive malignant pleural mesothelioma. The 
efficacy of VS-5584 is also being evaluated in advanced 
solid tumors in a phase I dose escalation study.
Image source: NCI
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•	 FDA Approves nivolumab 
to Treat Metastatic 
squamous non–small Cell 
Lung Cancer
open-label, multicenter, multinational randomized trial 
of 272 patients with the disease, who were treated with 
nivolumab (n=135) or docetaxel (n=137). Significantly 
prolonged median overall survival was observed in the 
nivolumab arm versus the docetaxel arm (9.2 versus 6 
months; hazard ratio [HR] = 0.59; P=0.00025). Fatigue, 
shortness of breath, musculoskeletal pain, decreased 
appetite, cough, nausea and, constipation were among 
the most common side effects of nivolumab. The most 
serious side effects were severe immune-mediated 
side effects involving healthy organs. Nivolumab was 
previously approved for unresectable or metastatic 
melanoma, and is being approved for metastatic 
squamous NSCLC 3 months in advance of the 
prescription drug user fee goal date.
The PD-1 inhibitor nivolumab has been approved by the FDA for 
the treatment of patients with metastatic squamous non-small cell 
lung cancer (NSCLC) who have progressed on or after platinum-
based chemotherapy. The approval was based on the findings of an 
Image credit: Ed Uthman | Flickr | CC BY 2.0 | 
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•	 Plain Packaging
the benefits of plain packaging, summarised in a BBC 
report as:
Plain packaging reduced unconscious triggers to 
smoke even in current smokers (Addiction 
2015;110(1):174–82)
Fewer people made cigarette packs visible in cafes and 
bars in Australia after the new rules (Addiction 
2014;109(4):653–62)
The size, shape and opening method do affect 
brand appeal and increase sales (Addiction 
2013;108(9):1658–68)
Removing branding draws more attention to health 
warnings in occasional smokers (Addiction 
2013;108(2):413–19)
Standardized packs are more effective than larger 
health warnings (Addiction 2012;107(6):1159–67)
http://www.bbc.com/news/health-31839859
http://www.irishtimes.com/news/health/
plain-packaging-for-cigarettes-signed-into-law-in-
ireland-1.2134138
http://www.bbc.com/news/health-31439211
It has been a good month for plain packaging. Ireland passed 
legislation for mandatory plain packaging for tobacco products on 
February 26. President Michael D. Higgins signed the legislation on 
March 10, making Ireland the first European member state to do so. 
In the UK, MPs have voted in favour of legislation for standardised 
packing for cigarettes (BBC). The vote on March 11 saw 367 votes 
for the legislation with 113 votes against it and was reached after 
the British government first considered standardised packaging in 
2011. The vote goes to the House of Lords on Monday March 16, 
where it is expected to pass and will be introduced in 2016. This 
brings to three the total number of countries in the world that have 
made such a move in tobacco control adding the UK and Ireland to 
Australia. The journal Addiction has published research supporting 
amicus curiae brief (law.cornell.edu) is a submission in 
a case by a person or group who is not party to a lawsuit, 
but who has a strong interest in the matter, in order to 
influence the court’s decision. In this case, according 
to the Investment Arbitratino Reporter, the tribunal has 
expressed satisfaction that the WHO and FCTC “bring 
new perspective, have significant interest and would 
appear to address matters within scope of dispute”. Of 
course they do you say? It is strange but in the smoke 
and mirrors world of tobacco industry disputes, such 
inevitable common sense comes at a struggle sometimes.
http://www.iareporter.com/articles/20150220_1
http://www.tobaccotactics.org/index.php/
Philip_Morris_vs_the_Government_of_Uruguay
•	 Tobacco Industry Legal 
Actions
A major side-effect of successful plain packaging legislation is the 
tobacco industry reaction. Big Bully, Philip Morris International 
(PMI) has been engaged in legal action against the Uruguay 
Government since 2010. Tobacco Tactics, a tobacco control research 
project at the University of Bath, outlines the legal campaign, an 
ISDS claim again three Uruguayan measures: (i) an increase in 
cigarette packet health warnings from 50–80% of the total pack size; 
(ii) the design of the message in the 80% space; (iii) restriction on 
one variation of cigarette per brand. On February 20, a tribunal at 
the Investment Arbitration Reporter tells us that the International 
Centre for Settlement of Disputes has permitted the WHO/FCTC 
to submit an amicus curiae brief in the PMI v Uruguay case. An 
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•	 e-Cigarette updates a proposal in Texas to prohibit the sale of e-cigarettes 
to minors. The reports quote a recent National Institute 
on Drug Abuse survey that indicates e-cigarette use in 
high school students from 8–17%. It is early days in 
Texas, state senators are reported as considering a “sin 
tax” (only in Texas??) on vapor products and no plans 
are yet in place to ban e-cigarette use in public places. 
And although e-cigarette representatives are reported as 
supportive of the ban on sales to minors, they expressed 
concerns about grouping e-cigarettes with tobacco 
products.
http://www.theoaklandpress.com/general-news/ 
20150216/rochester-joins-communities-with- 
e-cigarette-ban
http://trailblazersblog.dallasnews.com/2015/02/
lawmakers-consider-ban-on-e-cigarette-sales-to-
minors.html/
http://www.drugabuse.gov/publications/drugfacts/
high-school-youth-trends
Image source: Debora Cartagena | CDC
Two reports of local anti-tobacco or anti-tobacco-replacement 
activity tell us about e-cigarette bans. The Oakland Press News 
reports on a ban on e-cigarette sales to minors. Up to now, under-
18s could purchase e-cigarettes. On February the 9, Rochester 
City Council (Rochester, Michigan) passed a unanimous ruling 
to prohibit selling and providing e-cigarettes to minors. And a 
report from The Dallas Morning News from February 11 looks at 
